Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91% Market Closed
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Egetis Therapeutics AB (publ)
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Egetis Therapeutics AB (publ)
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Egetis Therapeutics AB (publ)
STO:EGTX
Cash Interest Paid
kr4.1m
CAGR 3-Years
1 501%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash Interest Paid
kr2.2m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash Interest Paid
kr1.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Cash Interest Paid
kr379k
CAGR 3-Years
-39%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Egetis Therapeutics AB (publ)
Glance View

Market Cap
2.4B SEK
Industry
Biotechnology

Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

EGTX Intrinsic Value
9.63 SEK
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Egetis Therapeutics AB (publ)'s Cash Interest Paid?
Cash Interest Paid
4.1m SEK

Based on the financial report for Dec 31, 2023, Egetis Therapeutics AB (publ)'s Cash Interest Paid amounts to 4.1m SEK.

What is Egetis Therapeutics AB (publ)'s Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
1 501%

Over the last year, the Cash Interest Paid growth was 4 000%. The average annual Cash Interest Paid growth rates for Egetis Therapeutics AB (publ) have been 1 501% over the past three years .

Back to Top